MedPath

Research on the development of the iPS cell stock derived from voluntary HLA homozygoues donor who have donated bone marrow etc.

Not Applicable
Recruiting
Conditions
healthy adult
Registration Number
JPRN-UMIN000016026
Lead Sponsor
Center for iPS Cell Research and Application (CiRA), Kyoto University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

1)Enrolling related studies of generating iPSC banks 2)The following viral infection: Hepatic Virus B Hepatic Virus C Human Immunodeficiency Virus Human T-cell leukemia virus Human parvovirus B19 Cytomegalovirus 3)The following microbial infection: Treponema pallidum West e Virus Chlamydiaceae Genus Neisseria Mycobacterium Malaria parasites(Plasmodium spp.) Babesia Trypanosoma cruzi Leishmania Trypanosoma brucei 4)Malignant neoplasm 5)Transmissible spongiform encephalopathy (including suspected case), Dementia or cognitive impairment, Stroke, Seizure 6)The following conditions: Particular or genetic/hereditary disorders Severe or uncontrolled metabolic or endocrinal disorders Connective tissue diseases Severe or uncontrolled hematologic diseases Severe or uncontrolled hepatic disorders

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Charactrization of iPS cells derived from HLA homozyougous donor.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath